Danger: Nature's new paper reveals that adenovirus vaccines can cause cancer

Lao Xue lasted ten years, the potential carcinogenicity gradually exposed with the development of biotechnology, more and more high-new medical methods were invented.
vaccines have evolved from traditional inactivated vaccines to vector vaccines, but can their safety really stand the test? On November 16th nature published an article entitled "A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells".
simple summary of the meaning of the article, is that adenovirus vectors have a carcinogenic effect on dogs.
: nature official website for the public, the concept of adenovirus vector is still from the new crown vaccine in various reports.
, Johnson and Johnson, and Concino all used the technology, according to an incomplete statistic.
: Dong Wu Securities this can be said to be a hot, but also front-end technology attributes good direction.
, of course, it must be stated here that the few mentioned in the article are not necessarily of the same type as those that are at risk of cancer if they are found to be at risk of cancer.
After all, the classification of adenovirus is also very diverse, such as the Ad5 vector COVID-19 vaccine developed by Academician Chen Wei is the use of weakened common cold virus, where the common cold virus is a adenovirus, and Oxford University's new coronavirus vaccine is the use of chimpanzee adenovirus as a carrier system.
the adenovirus and other products do not necessarily have a causal relationship, we do not have to panic too much.
but the study presents at least one potential risk factor.
expect too much from emerging technologies, often ignoring their toxic effects.
and many pharmaceutical products must pass the test of time in order to become a real therapeutic supplies.
this sense of risk out of control, in the event of an accident, often with multiple products with the same technical route lying gun.
this has also been seen many times in the development of the new crown vaccine, such as in May this year at Oxford University's adenovirus vector new crown vaccine research and development failure, directly in China's Consino shares also fell.
partly because of the public's limited ability to distinguish between technologies and because of the fear of uncertainty about emerging technologies.
of course, for a much-needed medical product, forced to use without sufficient data, itself has to consider risks and benefits.
this is also the meaning of post-market observation, if the relevant companies after the known drug has similar problems deliberately concealed, then the fine will be astronomical.
Actos, a diabetes drug that Takeda pharmaceuticals partnered with Lilly in 2014, was awarded $6 billion in punitive damages by a U.S. court for concealing a possible cancer risk.
, if other adenovirus vector drugs are found to have similar conditions, they will certainly be treated in the first place.
on the one hand is a social moral requirement, on the other hand, is also the enterprise to avoid a major disaster after the claim intention.
new technology may have its own flaws, just as Pfizer's new crown vaccine has the most stable storage temperature of minus 70 degrees Celsius.
this temperature can only be achieved by ultra-low temperature refrigerators, the conventional cold chain transport simply can not reach this temperature.
if you rely on this product, it makes sense to produce refrigeration equipment until the vaccine is officially put into production.
of course, the news broke, let the medical refrigerator Haier creatures suddenly came up, but the rate of decline is also relatively fast.
your weakness is your opponent's advantage.
the Moderna vaccine directly indicated that minus 20 degrees Celsius was stable for 6 months and 2-8 degrees C was stable for 30 days after thawing.
this is simply a crush on the Pfizer vaccine, to know that can be popular is the product, can not be popular can only belong to scientific research supplies.
scientific research supplies to clinical applications, there are countless gaps between them.
as to why the same mRNA vaccine, the storage temperature is so different, we do not know.
But after the baptism of double eleven, we all know that it is one thing to be able to sell, whether it can be delivered to the user is another, only to be able to reach the destination to have real sales.
a better quality of life if effective vaccines are available as soon as possible for people suffering from the outbreak.
is more likely than "which vaccine do you choose to fight" and the reality is, "At the moment we only have this vaccine, do you want to fight or not?"